Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides | Zendy

Pascal Clayette | Zendy; N Dereuddre-Bosquet | Zendy; Marc Martín | Zendy; Philippe Frétier | Zendy; Dominique Dormont | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides

Author(s) -

Pascal Clayette,

N Dereuddre-Bosquet,

Marc Martín,

Philippe Frétier,

Dominique Dormont

Publication year - 1997

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.41.4.875

Subject(s) - zidovudine , tumor necrosis factor alpha , in vivo , antagonism , alpha (finance) , virology , virus , pharmacology , biology , medicine , immunology , viral disease , biochemistry , receptor , construct validity , microbiology and biotechnology , nursing , patient satisfaction

Tumor necrosis factor alpha (TNF-alpha) is overexpressed during human immunodeficiency virus (HIV) infection. RP 55778, a TNF-alpha synthesis inhibitor, decreases HIV replication in monocytes/macrophages. Therapeutic use of RP 55778 in vivo, like that of other biological response modifiers, would theoretically require association with dideoxynucleosides. We have evaluated here the combinatory effects of zidovudine (AZT) or dideoxyinosine (ddI) and RP 55778. This TNF-alpha inhibitor antagonizes the antiviral effects of both dideoxynucleosides, especially AZT. The more favorable anti-HIV activity of ddI in resting cells may explain these unequal degrees of antagonism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research